CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
Ontology highlight
ABSTRACT: This is an open-label, dose-escalation, phase I trial of the safety and efficacy of anti-CEA intraperitoneal CAR-T infusions for treatment in patients with CEA-expressing adenocarcinoma peritoneal metastases or malignant ascites.
DISEASE(S): Adenocarcinoma,Carcinoma,Colorectal Cancer,Breast Cancer,Peritoneal Carcinomatosis,Peritoneal Metastases,Peritoneal Neoplasms,Pancreas Cancer,Neoplasm Metastasis,Carcinoembryonic Antigen,Gastric Cancer,Ascites,Pancreatic Neoplasms
PROVIDER: 2285031 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA